In a statement last week, the WHO Director described the rise in Mpox infections in the Democratic Republic of Congo and several neighboring countries as a public health emergency of international concern. Consequently, the WHO has initiated the process for Emergency Use Listing for Mpox vaccines, particularly for low-income countries. This measure also enables the Vaccine Alliance Gavi to procure and distribute vaccines.
As an MSP, Gavi unites governments, research agencies, vaccines manufacturers, civil society organizations, and UN institutions such as the WHO and UNICEF. Since its foundation in 2000, the Vaccine Alliance has thereby helped to immunize more than one billion children and coordinated efforts to provide and distribute vaccines in the context of the COVID-19 pandemic. Gavi, therefore, plays a crucial role in reaching SDG 3 Good Health and Well-Being.
In collaboration with partners and countries, Gavi is now also addressing the Mpox emergency. For example, it is supporting local efforts in the currently affected region, coordinating the creation of a global stockpile of Mpox vaccines and accelerating procurement from manufacturers. Based on the experience of the COVID-19 pandemic, the MAP has also set up a First Response Fund to ensure rapid financing of vaccines and is investing in a learning agenda to improve future vaccination measures.
This underlines the importance of MSP in bringing together public institutions, research institutions, the private sector and civil society to respond to health emergencies such as COVID-19 or Mpox and take important steps towards good health and well-being for all.
You can find further information on Gavi here.
